Soluble and tissue biomarkers in ankylosing spondylitis

Best Practice and Research: Clinical Rheumatology

Volumn 24, Issue 5, 2010, Pages 671-682

  De Vlam, Kurt ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

ankylosing spondylitis; biomarkers; damage; disease activity

Indexed keywords

ADALIMUMAB; ALKALINE PHOSPHATASE BONE ISOENZYME; AMYLOID A PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; ETANERCEPT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA B27 ANTIGEN; INFLIXIMAB; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; STROMELYSIN; TUMOR NECROSIS FACTOR INHIBITOR; VASCULOTROPIN;

ANKYLOSING SPONDYLITIS; BONE INJURY; CARTILAGE INJURY; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT MONITORING; PHYSICIAN; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; HLA-B27 ANTIGEN; HUMANS; SENSITIVITY AND SPECIFICITY; SPONDYLITIS, ANKYLOSING;

EID: 78049419054     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2010.05.009     Document Type: Review

References (58)

1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clinical Pharmacology and Therapeutics 69 3 2001 89 95
2. D. Mildvan, A. Landay, V. De Gruttola, S.G. Machado, and J. Kagan An approach to the validation of markers for use in AIDS clinical trials Clinical Infectious Diseases 24 5 1997 764 774
3. W.P. Maksymowych, R. Landewe, and M. Boers Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials The Journal of Rheumatology 34 3 2007 634 640
4. W.P. Maksymowych, R. Landewé, and P.P. Tak Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria The Journal of Rheumatology 36 8 2009 Aug 1785 1791
5. A.M. van Tubergen, and R.B. Landewé Tools for monitoring spondyloarthritis in clinical practice Nature Reviews. Rheumatology 5 11 2009 Nov 608 615
6. D. van der Heijde, E. Lie, and T.K. Kvien Assessment of SpondyloArthritis international Society (ASAS). ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis Annals of the Rheumatic Diseases 68 12 2009 Dec 1811 1818
7. S. van der Linden, H.A. Valkenburg, and A. Cats Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria Arthritis and Rheumatism 27 4 1984 Apr 361 368
8. M. Dougados, S. van der Linden, and R. Juhlin The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy Arthritis and Rheumatism 34 10 1991 Oct 1218 1227
9. B. Amor, M. Dougados, and M. Mijiyawa Criteria of the classification of spondylarthropathies Revue du rhumatisme et des maladies ostéo- articulaires 57 2 1990 Feb 85 89
10. M. Rudwaleit, R. Landewé, and D. van der Heijde The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal Annals of the Rheumatic Diseases 68 6 2009 Jun 770 776
11. M. Rudwaleit, D. van der Heijde, and R. Landewé The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection Annals of the Rheumatic Diseases 68 6 2009 Jun 777 783
12. A. Spoorenberg, D. van der Heijde, and E. de Klerk Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis The Journal of Rheumatology 26 4 1999 Apr pp. 980-41
13. J. Braun, J. Brandt, and J. Listing Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial Arthritis and Rheumatism 48 8 2003 Aug 2224 2233
14. W.P. Maksymowych, R.D. Inman, and D. Salonen Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis Arthritis and Rheumatism 53 5 2005 Oct 15 703 709
15. M. Rudwaleit, S. Schwarzlose, and E.S. Hilgert MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis Annals of the Rheumatic Diseases 67 9 2008 Sep 1276 1278
16. M.A. Brown Progress in spondylarthritis. Progress in studies of the genetics of ankylosing spondylitis Arthritis Research & Therapy 11 5 2009 254
17. M. Rudwaleit, D. van der Heijde, M.A. Khan, J. Braun, and J. Sieper How to diagnose axial spondyloarthritis early Annals of the Rheumatic Diseases 63 5 2004 May 535 543
18. F.P. Luyten, R.J. Lories, P. Verschueren, K. de Vlam, and R. Westhovens Contemporary concepts of inflammation, damage and repair in rheumatic diseases Best Practice & Research. Clinical Rheumatology 20 5 2006 Oct 829 848
19. S.T. Choi, J.H. Kim, and E.J. Kang Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis Rheumatology (Oxford) 47 12 2008 Dec 1775 1779
20. D. Grcevic, Z. Jajic, and N. Kovacic Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness The Journal of Rheumatology 37 2 2010 Feb 246 256
21. B. Vander Cruyssen, C. Ribbens, and A. Boonen The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice Annals of the Rheumatic Diseases 66 8 2007 Aug 1072 1077
22. C.H. Chen, H.T. Liao, and H.A. Chen Soluble triggering receptor expressed on myeloid cell-1 (sTREM-1): a new mediator involved in early ankylosing spondylitis The Journal of Rheumatology 35 9 2008 Sep 1846 1848
23. F.C. Arnett, S.M. Edworthy, and D.A. Bloch The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis and Rheumatism 31 1988 315 324
24. J.M. Kim, and M.H. Weisman When does rheumatoid arthritis begin and why do we need to know? Arthritis and Rheumatism 43 2000 473 484
25. D. Baeten, E. Kruithof, and L. De Rycke Diagnostic classification of spondylarthropathy and rheumatoid arthritis by synovial histopathology: a prospective study in 154 consecutive patients Arthritis and Rheumatism 50 9 2004 Sep 2931 2941
26. D. van der Heijde, A. Calin, and M. Dougados Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis The Journal of Rheumatology 26 4 1999 Apr 951 954
27. N.J. Sheehan, B.M. Slavin, M.P. Donovan, J.N. Mount, and J.A. Mathews Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis British Journal of Rheumatology 25 2 1986 May 171 174
28. J. Ruof, and G. Stucki Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review The Journal of Rheumatology 26 4 1999 Apr 966 970
29. S.Y. Jung, M.C. Park, Y.B. Park, and S.K. Lee Serum amyloid a as a useful indicator of disease activity in patients with ankylosing spondylitis Yonsei Medical Journal 48 2 2007 Apr 30 218 224
30. J. Zhu, and D.T. Yu Matrix metalloproteinase expression in the spondyloarthropathies Current Opinion in Rheumatology 18 4 2006 Jul 364 368
31. D. Wendling, J.P. Cedoz, and E. Racadot Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNF-alpha antagonist therapy Joint Bone Spine 75 5 2008 Oct 559 562
32. C.H. Chen, K.C. Lin, and D.T. Yu Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity Rheumatology (Oxford) 45 4 2006 Apr 414 420
33. C. Yang, J. Gu, and M. Rihl Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis Arthritis and Rheumatism 51 5 2004 Oct 15 691 699
34. P.T. Yang, H. Kasai, and W.G. Xiao Increased expression of macrophage colony-stimulating factor in ankylosing spondylitis and rheumatoid arthritis Annals of the Rheumatic Diseases 65 12 2006 Dec 1671 1672
35. R.J. Franois, L. Neure, J. Sieper, and J. Braun Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases Annals of the Rheumatic Diseases 65 6 2006 Jun 713 720
36. A. Bal, E. Unlu, and G. Bahar Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis Clinical Rheumatology 26 2 2007 Feb 211 215
37. J. Gratacós, A. Collado, and X. Filella Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity British Journal of Rheumatology 33 10 1994 Oct 927 931
38. S. Visvanathan, C. Wagner, and J.C. Marini Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab Annals of the Rheumatic Diseases 67 4 2008 April 511 517
39. H. Appel, L. Janssen, and J. Listing Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment Arthritis Research & Therapy 10 5 2008 R125
40. A. Spoorenberg, K. de Vlam, and S. van der Linden Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2 years The Journal of Rheumatology 31 1 2004 Jan 125 132
41. T.H. Kim, M. Stone, and U. Payne Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response Arthritis and Rheumatism 52 3 2005 Mar 885 891
42. M.C. Park, S.J. Chung, Y.B. Park, and S.K. Lee Bone and cartilage turnover markers, bone mineral density, and radiographic damage in men with ankylosing spondylitis Yonsei Medical Journal 49 2 2008 Apr 30 288 294
43. D. Vosse, R. Landewé, and P. Garnero Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis Rheumatology (Oxford) 47 8 2008 Aug 1219 1222
44. H. Appel, G. Ruiz-Heiland, and J. Listing Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis Arthritis and Rheumatism 60 11 2009 Nov 3257 3262
45. W.P. Maksymowych, R. Landewé, and B. Conner-Spady Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis Arthritis and Rheumatism 56 6 2007 Jun 1846 1853
46. U. Lange, J. Teichmann, J. Strunk, U. Müller-Ladner, and K.L. Schmidt Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis Osteoporosis International 16 12 2005 Dec 1999 2004
47. H.R. Kim, S.H. Lee, and H.Y. Kim Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS) Rheumatology (Oxford) 45 10 2006 Oct 1197 1200
48. J.J. Anderson, G. Baron, D. van der Heijde, D.T. Felson, and M. Dougados Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis Arthritis and Rheumatism 44 8 2001 Aug 1876 1886
49. J. Brandt, A. Khariouzov, and J. Listing Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis Arthritis and Rheumatism 48 6 2003 Jun 1667 1675
50. J.C. Davis Jr., D. Van Der Heijde, J. Braun Enbrel Ankylosing Spondylitis Study Group Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial Arthritis and Rheumatism 48 11 2003 Nov 3230 3236
51. D. van der Heijde, B. Dijkmans, P. Geusens Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT) Arthritis and Rheumatism 52 2 2005 Feb 582 591
52. J. Braun, J. Brandt, and J. Listing Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial Lancet 359 9313 2002 Apr 6 1187 1193
53. D. van der Heijde, A. Kivitz, M.H. Schiff ATLAS Study Group Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial Arthritis and Rheumatism 54 7 2006 Jul 2136 2146
54. C. Romero-Sánchez, W.H. Robinson, and B.H. Tomooka Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis Clinical Rheumatology 27 11 2008 Nov 1429 1435
55. J.H. Woo, H.J. Lee, I.H. Sung, and T.H. Kim Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept The Journal of Rheumatology 34 8 2007 Aug 1753 1759
56. M.A. Stone, U. Payne, C. Pacheco-Tena, and R.D. Inman Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis Annals of the Rheumatic Diseases 63 1 2004 Jan 84 87
57. W.P. Maksymowych, A.R. Poole, and L. Hiebert Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis The Journal of Rheumatology 32 10 2005 Oct 1911 1917
58. W.P. Maksymowych, G.S. Jhangri, and R.G. Lambert Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety The Journal of Rheumatology 29 5 2002 May 959 965